Humanigen, Inc

(NASDAQ:HGEN)

Latest On Humanigen, Inc (HGEN):

Date/Time Type Description Signal Details
2022-12-23 03:25 ESTNewsHumanigen to pay Catalent Pharma $12M to settle supply agreement disputeN/A
2022-11-15 14:08 ESTNewsHumanigen GAAP EPS of -$0.23 misses by $0.04, revenue of $0.22M misses by $0.13MN/A
2022-08-13 06:51 ESTNewsHumanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69MN/A
2022-07-14 02:12 ESTNewsHumanigen hits 52-week low as Cantor cuts target to $2 on setback for COVID therapyN/A
2022-07-13 11:14 ESTNewsHumanigen plunges 57% as trial for COVID-19 therapy failsN/A
2022-07-06 17:40 ESTNewsHumanigen jumps over 10% after peer-reviewed data on COVID-19 therapyN/A
2022-06-16 13:52 ESTNewsHumanigen gains as it enters pact with PCI Pharma Services in UK for lenzilumabN/A
2022-05-27 15:23 ESTNewsHumanigen (HGEN) Presents At H.C. Wainwright Global Investment Conference - SlideshowN/A
2022-05-05 19:41 ESTNewsHumanigen GAAP EPS of -$0.32 beats by $0.14, revenue of $1.04M beats by $0.83MN/A
2022-04-05 20:13 ESTNewsHumanigen (HGEN) April 2022 IR Presentation - SlideshowN/A
2022-03-21 04:59 ESTNewsHumanigen (HGEN) Presents at the ROTH 34th Annual Conference 2022 - SlideshowN/A
2022-03-12 01:04 ESTNewsHumanigen gains the most in nearly a year after new insider filing by science chiefN/A
2022-03-04 17:37 ESTNewsHumanigen gains as CEO more than doubles stakeN/A
2022-03-01 19:54 ESTNewsHumanigen GAAP EPS of -$0.53 beats by $0.24, revenue of $1.04M misses by $132.52MN/A
2022-02-09 06:27 ESTNewsHumanigen inks pact with Cenexi to make potential COVID-19 drug lenzilumab in FranceN/A
2022-01-05 16:06 ESTNewsHumanigen expects data from phase 2/3 study of lenzilumab by early Q2 following enrollmentN/A
2022-01-03 15:22 ESTNewsHumanigen says lenzilumab response in hospitalized COVID-19 patients correlates with CRP levelsN/A
2021-12-02 11:55 ESTNewsPositive results from Humanigen's lenzilumab study in COVID-19 published in The LancetN/A
2021-11-13 10:35 ESTNewsHumanigen EPS misses by $0.14, beats on revenueN/A
2021-10-26 09:59 ESTNewsHumanigen gets dosing underway in mid-stage lenzilumab leukemia trialN/A
2021-10-25 11:33 ESTNewsHumanigen says lead drug grouped among most promising therapies for COVID-19 in EUN/A
2021-10-23 02:10 ESTNewsHumanigen announces plans to start phase 1b study of ifabotuzumab in solid tumorsN/A
2021-10-20 01:14 ESTNewsHumanigen finds biomarker that best identifies patients to benefit from COVID treatmentN/A
2021-10-08 21:42 ESTNewsHumanigen inks pact with Clinigen for lenzilumab managed access program in EuropeN/A
2021-10-02 04:59 ESTNewsHumanigen submits all planned modules for lenzilumab's conditional approval to the MHRAN/A
2021-09-30 07:46 ESTNewsHumanigen reports late-stage lenzilumab data in COVID-19 at IDweek 2021N/A
2021-09-28 10:20 ESTNewsHumanigen discloses key step in pre-submission seeking EU nod for COVID-19 therapyN/A
2021-09-25 16:51 ESTNewsKadmon, Adagio top weekly healthcare gainers; Forte Biosciences and Humanigen trailN/A
2021-09-22 19:20 ESTNewsHumanigen (HGEN) Presents At Global Healthcare Virtual Conference 2021 - SlideshowN/A
2021-09-11 10:27 ESTNewsHumanigen extends losses as setback for COVID-19 therapy prompts more bearish viewsN/A
2021-09-11 10:27 ESTNewsKadmon, Adagio top weakly healthcare gainers; Forte Biosciences and Humanigen trailN/A
2021-09-09 19:00 ESTNewsHumanigen sheds more than half after FDA declined emergency use approval of lenzilumab in COVID-19N/A
2021-08-13 07:34 ESTNewsHumanigen says no formal timeline for FDA approval of COVID-19 therapyN/A
2021-08-13 07:34 ESTNewsHumanigen EPS misses by $0.37, beats on revenueN/A
2021-07-31 03:41 ESTNewsNIH advances Humanigen's lenzilumab COVID-19 trialN/A
2021-07-22 17:32 ESTNewsHumanigen submits lenzilumab COVID-19 EUA application to FDAN/A
2021-07-22 17:28 ESTNewsHumanigen begins rolling submission for lenzilumab in COVID-19 in U.K.N/A
2021-07-22 17:27 ESTNewsHumanigen stock gains as lenzilumab nabs expedited rolling review in U.K. for COVID-19N/A
2021-07-22 17:25 ESTNewsHumanigen’s partner in South Korea cleared to start early-stage trial for COVID-19 therapyN/A
2021-05-07 02:17 ESTNewsOppenheimer sees big potential for Humanigen's COVID-19 therapy lenlizumabN/A
2021-05-06 06:08 ESTNewsHumanigen is on the rise after publication of Phase 3 data for COVID-19 therapyN/A
2021-04-21 12:52 ESTNewsHumanigen picks ex-AstraZeneca executive for medical chief roleN/A
2021-04-19 23:59 ESTNewsHumanigen achieves positive outcome for Lenzilumab in small early-stage studyN/A
2021-04-09 17:02 ESTNewsHumanigen to present positive Phase 1 data for brain cancer therapy at AACR meetingN/A
2021-03-31 15:15 ESTNewsHumanigen secures $92.5M via equity raiseN/A
2021-03-30 00:34 ESTNewsHumanigen surges on positive Phase 3 data for COVID-19 therapyN/A
2021-03-30 00:34 ESTNewsDespite spike on COVID-19 therapy data, J.P. Morgan remains neutral on HumanigenN/A
2021-03-30 00:34 ESTNewsRBC sees Avid Biosciences benefiting from Humanigen COVID candidate dataN/A
2021-03-19 09:58 ESTNewsHumanigen (HGEN) Presents At Oppenheimer 31st Annual Healthcare Conference - SlideshowN/A
2021-03-12 06:38 ESTFinancialsCompany financials have been released.Neutral

About Humanigen, Inc (HGEN):

Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment and/or prevention of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that has completed Phase I clinical trial in patients with chronic myelomonocytic leukemia. It also develops Ifabotuzumab, a monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005, an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic disorders. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was incorporated in 2000 and is based in Burlingame, California.

HGEN Quotes by TradingView

See Advanced Chart

General

  • Name Humanigen, Inc
  • Symbol HGEN
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 10
  • Last Split Factor1:5
  • Last Split Date2020-09-14
  • Fiscal Year EndDecember
  • IPO Date2013-01-31
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.humanigen.com
View More

Valuation

  • Trailing PE 3.03
  • Forward PE 4.68
  • Price/Sales (Trailing 12 Mt.) 2107.6
  • Price/Book (Most Recent Quarter) 20.89
  • Enterprise Value Revenue 2832.42
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate $4.92
  • Next Year EPS Estimate $3.46
  • Next Quarter EPS Estimate -$0.53
  • Operating Margin -28269%
  • Return on Assets -160%
  • Return on Equity -573%
  • Revenue 312000
  • Earnings Per Share -$0.09
  • Revenue Per Share $0.01
  • Gross Profit 312000
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 878.18 million
  • EBITDA -9277500
  • Analyst Target Price $29.17
  • Book Value Per Share $0.88
View More

Share Statistics

  • Shares Outstanding 53.48 million
  • Shares Float 32.15 million
  • % Held by Insiders 4028%
  • % Held by Institutions 30.56%
  • Shares Short 2.32 million
  • Shares Short Prior Month 2.39 million
  • Short Ratio 2.84
  • Short % of Float 14%
  • Short % of Shares Outstanding 4%
View More

Technicals

  • Beta -1.41
  • 52 Week High $33.95
  • 52 Week Low $3.5
  • 50 Day Moving Average 18.82
  • 200 Day Moving Average 14.2
View More

Dividends

  • Dividend Date 2020-09-14
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Humanigen, Inc (HGEN) Dividend Calendar:

HGEN's last dividend payment was made to shareholders on September 14, 2020.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Humanigen, Inc (HGEN) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-10$312000-$0.63-$0.676.19%
2020-09-302020-11-10$N/A-$0.71-$0.57-25.29%
2020-06-302020-08-14$N/A-$0.80
2020-03-312020-05-15$N/A-$0.02
2019-09-302019-10-28$N/A-$0.02
2019-06-302019-08-12$N/A-$0.03
2019-03-312019-05-03$N/A-$0.02
2018-12-312019-03-26$N/A-$0.02
2018-09-302018-11-06$N/A-$0.02
2018-06-302018-08-20$N/A-$0.12
2018-03-312018-05-15$N/A-$0.52
2017-12-312018-02-28$N/A-$1.04
2017-09-302017-11-10$N/A-$2.40
2017-06-302017-09-25$N/A-$2.05
2017-03-312017-05-16$N/A-$1.85
2016-12-312017-03-16$N/A-$1.69
2016-09-302016-11-11$N/A-$1.52
2016-06-302016-09-26$N/A-$13.17
2016-03-312016-05-10$N/A-$6.10
2015-09-302015-11-05$N/A-$8.00
2015-06-302015-08-10$N/A-$7.30-$8.4013.1%
2015-03-312015-05-11$N/A-$11.60-$12.003.33%
2014-12-312015-03-16$N/A-$11.60-$12.003.33%
2014-09-302014-11-06$N/A-$9.60-$13.7029.93%
2014-06-302014-08-07$N/A-$12.00-$13.4010.45%
2014-03-312014-05-08$N/A-$12.80-$15.2015.79%
2013-12-312014-03-13$4000-$2.00-$3.3139.58%
2013-09-302013-11-12$9000-$3.76-$3.811.31%
2013-06-302013-08-19$15000-$3.92-$3.28-19.51%
2013-03-312013-05-14$16000-$4.40-$3.60-22.22%
2012-12-312013-03-27$18000-$76.96-$20.48-275.78%

Humanigen, Inc (HGEN) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 116.93 million N/A N/A 659000 474000
Income Before Tax -32.3 million N/A N/A -2.47 million -2.03 million
Selling General Administrative 27.48 million N/A N/A 1.4 million 1.21 million
Gross Profit 312000 N/A N/A N/A 1.75 million
Ebit -32.3 million N/A N/A -2.06 million -1.68 million
Operating Income -32.3 million N/A N/A -2.06 million -1.68 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue 312000 N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A -1.75 million
Total Other Income Expense Net N/A N/A N/A N/A N/A
Net Income From Continuing Operations -32.3 million N/A N/A -2.47 million -2.03 million
Net Income Applicable to Common Shares -32.3 million -30.75 million -24.02 million -2.47 million -2.03 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A N/A
Change to Liabilities 6.63 million -3.8 million 860000 1.11 million 359000
Total Cash Flow from Investing Activities -20000 N/A N/A N/A N/A
Net Borrowings -8000 -3.34 million 467000 350000 245000
Total Cash Flow from Financial Activities N/A N/A 532000 535000 245000
Change to Operating Activities -609000 5.37 million 703000 -148000 57000
Change in Cash N/A N/A -75000 -14000 -934000
Total Cash from Operating Activities -23.54 million -22.01 million -607000 -549000 -1.18 million
Depreciation N/A N/A N/A N/A N/A
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A -505000
Change to Net Income 1.18 million 443000 297000 511000 794000
Capital Expenditures N/A N/A N/A N/A N/A
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 22.76 million N/A N/A 16.72 million 14.84 million
Total Stockholder Equity 45.55 million N/A N/A -16.29 million -14.32 million
Other Current Liabilities 1.87 million N/A N/A 2.15 million 2 million
Total Assets 68.3 million N/A N/A 432000 523000
Common Stock 52000 52000 210000 114000 114000
Other Current Assets 475000 N/A N/A 293000 309000
Retained Earnings -374.43 million -342.14 million -311.38 million -287.36 million -284.9 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets N/A 70000 70000 71000 71000
Cash 67.74 million N/A N/A 68000 143000
Total Current Liabilities 20.42 million 14.87 million N/A 15.43 million 13.59 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment N/A N/A N/A N/A N/A
Total Current Assets 68.21 million 92.05 million N/A 361000 452000
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 45.53 million 77.25 million 31.6 million -16.29 million -14.32 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A 1.29 million 1.25 million
Inventory N/A N/A N/A N/A N/A
Accounts Payable 18.54 million 8.74 million N/A 5.91 million 5.05 million

Humanigen, Inc (HGEN) Chart:

Humanigen, Inc (HGEN) News:

Below you will find a list of latest news for Humanigen, Inc (HGEN) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Humanigen, Inc (HGEN) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest HGEN Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST101$2.32
Jun 13, 2022 7:59 PM EST283$2.32
Jun 13, 2022 7:59 PM EST315$2.32
Jun 13, 2022 7:59 PM EST119$2.32
Jun 13, 2022 7:59 PM EST100$2.32

Humanigen, Inc (HGEN) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000138713120006163/0001387131-20-006163-index.htm
2020-06-29UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1293310/000000000020005813/0000000000-20-005813-index.htm
2020-09-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1293310/000000000020008403/0000000000-20-008403-index.htm
2020-06-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1293310/000093583620000338/0000935836-20-000338-index.htm
2020-04-07SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1293310/000101359420000382/0001013594-20-000382-index.htm
2020-04-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000101359420000383/0001013594-20-000383-index.htm
2020-09-22SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1293310/000101359420000705/0001013594-20-000705-index.htm
2020-09-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000101359420000709/0001013594-20-000709-index.htm
2020-06-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1293310/000110465920072892/0001104659-20-072892-index.htm
2019-12-04424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1293310/000121465919007572/0001214659-19-007572-index.htm
2019-12-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1293310/000121465919007745/0001214659-19-007745-index.htm
2019-12-16424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1293310/000121465919007747/0001214659-19-007747-index.htm
2019-12-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465919007750/0001214659-19-007750-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465919007751/0001214659-19-007751-index.htm
2019-12-31424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1293310/000121465919008064/0001214659-19-008064-index.htm
2019-12-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1293310/000121465919008065/0001214659-19-008065-index.htm
2020-01-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920000573/0001214659-20-000573-index.htm
2020-01-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920000574/0001214659-20-000574-index.htm
2020-01-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920000575/0001214659-20-000575-index.htm
2020-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920000663/0001214659-20-000663-index.htm
2020-01-31424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1293310/000121465920000761/0001214659-20-000761-index.htm
2020-01-318-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1293310/000121465920000762/0001214659-20-000762-index.htm
2020-03-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1293310/000121465920002661/0001214659-20-002661-index.htm
2020-03-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1293310/000121465920002796/0001214659-20-002796-index.htm
2020-03-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1293310/000121465920002832/0001214659-20-002832-index.htm
2020-03-23POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1293310/000121465920002836/0001214659-20-002836-index.htm
2020-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920003153/0001214659-20-003153-index.htm
2020-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920003154/0001214659-20-003154-index.htm
2020-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920003155/0001214659-20-003155-index.htm
2020-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920003156/0001214659-20-003156-index.htm
2020-04-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1293310/000121465920003203/0001214659-20-003203-index.htm
2020-04-074/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920003236/0001214659-20-003236-index.htm
2020-04-074/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920003237/0001214659-20-003237-index.htm
2020-04-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1293310/000121465920003861/0001214659-20-003861-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1293310/000121465920004153/0001214659-20-004153-index.htm
2020-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1293310/000121465920004718/0001214659-20-004718-index.htm
2020-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920004918/0001214659-20-004918-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920004950/0001214659-20-004950-index.htm
2020-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1293310/000121465920005413/0001214659-20-005413-index.htm
2020-06-15S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1293310/000121465920005577/0001214659-20-005577-index.htm
2020-06-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1293310/000121465920005663/0001214659-20-005663-index.htm
2020-06-16POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1293310/000121465920005677/0001214659-20-005677-index.htm
2020-07-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1293310/000121465920006149/0001214659-20-006149-index.htm
2020-07-09S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1293310/000121465920006234/0001214659-20-006234-index.htm
2020-07-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1293310/000121465920006260/0001214659-20-006260-index.htm
2020-07-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920006264/0001214659-20-006264-index.htm
2020-07-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1293310/000121465920006613/0001214659-20-006613-index.htm
2020-08-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1293310/000121465920006660/0001214659-20-006660-index.htm
2020-08-03S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1293310/000121465920006716/0001214659-20-006716-index.htm
2020-08-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1293310/000121465920006719/0001214659-20-006719-index.htm
2020-08-03PRE 14COther preliminary information statementshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920006723/0001214659-20-006723-index.htm
2020-08-05424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1293310/000121465920006803/0001214659-20-006803-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1293310/000121465920006884/0001214659-20-006884-index.htm
2020-08-10424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1293310/000121465920006886/0001214659-20-006886-index.htm
2020-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1293310/000121465920007189/0001214659-20-007189-index.htm
2020-08-14DEF 14COther definitive information statementshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920007208/0001214659-20-007208-index.htm
2020-08-17424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1293310/000121465920007229/0001214659-20-007229-index.htm
2020-08-28S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1293310/000121465920007537/0001214659-20-007537-index.htm
2020-09-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920007676/0001214659-20-007676-index.htm
2020-09-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1293310/000121465920007694/0001214659-20-007694-index.htm
2020-09-04424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1293310/000121465920007696/0001214659-20-007696-index.htm
2020-09-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1293310/000121465920007783/0001214659-20-007783-index.htm
2020-09-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1293310/000121465920007809/0001214659-20-007809-index.htm
2020-09-11424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1293310/000121465920007813/0001214659-20-007813-index.htm
2020-09-11S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1293310/000121465920007815/0001214659-20-007815-index.htm
2020-09-14S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920007835/0001214659-20-007835-index.htm
2020-09-158-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1293310/000121465920007851/0001214659-20-007851-index.htm
2020-09-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1293310/000121465920007853/0001214659-20-007853-index.htm
2020-09-18424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1293310/000121465920007954/0001214659-20-007954-index.htm
2020-09-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1293310/000121465920007978/0001214659-20-007978-index.htm
2020-09-21424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1293310/000121465920007979/0001214659-20-007979-index.htm
2020-09-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920008050/0001214659-20-008050-index.htm
2020-09-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920008051/0001214659-20-008051-index.htm
2020-09-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920008052/0001214659-20-008052-index.htm
2020-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920008352/0001214659-20-008352-index.htm
2020-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920008368/0001214659-20-008368-index.htm
2020-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920008371/0001214659-20-008371-index.htm
2020-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1293310/000121465920008467/0001214659-20-008467-index.htm
2020-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000121465920008470/0001214659-20-008470-index.htm
2020-10-07424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1293310/000121465920008471/0001214659-20-008471-index.htm
2020-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1293310/000121465920009167/0001214659-20-009167-index.htm
2020-11-04424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1293310/000121465920009171/0001214659-20-009171-index.htm
2020-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1293310/000121465920009193/0001214659-20-009193-index.htm
2020-11-06424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1293310/000121465920009195/0001214659-20-009195-index.htm
2020-09-18CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1293310/000135445720000484/0001354457-20-000484-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000138713120005655/0001387131-20-005655-index.htm
2020-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000138713120005739/0001387131-20-005739-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000138713120006163/0001387131-20-006163-index.htm
2020-07-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000138713120006574/0001387131-20-006574-index.htm
2020-07-21SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1293310/000138713120006581/0001387131-20-006581-index.htm
2020-07-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000138713120006895/0001387131-20-006895-index.htm
2020-08-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1293310/000138713120007329/0001387131-20-007329-index.htm
2020-04-06EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1293310/999999999520000686/9999999995-20-000686-index.htm
2020-06-23EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1293310/999999999520001504/9999999995-20-001504-index.htm
2020-08-05EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1293310/999999999520002027/9999999995-20-002027-index.htm
2020-09-14EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1293310/999999999520002442/9999999995-20-002442-index.htm

Humanigen, Inc (HGEN) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Humanigen, Inc (HGEN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 4028%
Institutional Ownership: 3056%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-04-01Cheryl BuxtonDirectorBuy10,824.001.2012,988.8015,400.00https://www.sec.gov/Archives/edgar/data/1293310/000121465920003155/0001214659-20-003155-index.htm
2020-08-10BAY LTD. NOMIS10% Share HolderSell17,100.005.0486,098.5032,662,170.00https://www.sec.gov/Archives/edgar/data/1293310/000138713120007329/0001387131-20-007329-index.htm
2020-07-28BAY LTD. NOMIS10% Share HolderSell10,000.005.6656,550.0032,679,270.00https://www.sec.gov/Archives/edgar/data/1293310/000138713120006895/0001387131-20-006895-index.htm
2020-07-20BAY LTD. NOMIS10% Share HolderSell261,915.005.001,309,575.0032,689,270.00https://www.sec.gov/Archives/edgar/data/1293310/000138713120006574/0001387131-20-006574-index.htm
2020-07-17BAY LTD. NOMIS10% Share HolderSell38,085.005.01190,615.4332,951,185.00https://www.sec.gov/Archives/edgar/data/1293310/000138713120006574/0001387131-20-006574-index.htm
2020-06-30BAY LTD. NOMIS10% Share HolderSell3,000.004.9114,739.0032,989,270.00https://www.sec.gov/Archives/edgar/data/1293310/000138713120006163/0001387131-20-006163-index.htm
2020-06-16BAY LTD. NOMIS10% Share HolderSell35,000.005.73200,651.5032,992,270.00https://www.sec.gov/Archives/edgar/data/1293310/000138713120005739/0001387131-20-005739-index.htm
2020-06-15BAY LTD. NOMIS10% Share HolderSell30,000.005.50165,147.0033,027,270.00https://www.sec.gov/Archives/edgar/data/1293310/000138713120005739/0001387131-20-005739-index.htm
2020-06-10BAY LTD. NOMIS10% Share HolderSell5,000.003.4817,385.0033,057,270.00https://www.sec.gov/Archives/edgar/data/1293310/000138713120005655/0001387131-20-005655-index.htm
2020-06-09BAY LTD. NOMIS10% Share HolderSell35,000.003.65127,785.0033,062,270.00https://www.sec.gov/Archives/edgar/data/1293310/000138713120005655/0001387131-20-005655-index.htm
2020-06-04BAY LTD. NOMIS10% Share HolderSell106,000.003.03320,650.0033,097,270.00https://www.sec.gov/Archives/edgar/data/1293310/000138713120005655/0001387131-20-005655-index.htm
2020-06-03BAY LTD. NOMIS10% Share HolderSell101,010.002.98301,312.8333,203,270.00https://www.sec.gov/Archives/edgar/data/1293310/000138713120005655/0001387131-20-005655-index.htm
2020-06-02BAY LTD. NOMIS10% Share HolderSell263,250.002.18574,148.2533,304,280.00https://www.sec.gov/Archives/edgar/data/1293310/000138713120005655/0001387131-20-005655-index.htm
2020-03-20BAY LTD. NOMIS10% Share HolderSell6,000.002.0012,000.0033,567,530.00https://www.sec.gov/Archives/edgar/data/1293310/000138713120005655/0001387131-20-005655-index.htm
2020-01-22Rainer J. BoehmDirectorBuy43,421.000.3816,499.98403,588.00https://www.sec.gov/Archives/edgar/data/1293310/000121465920000575/0001214659-20-000575-index.htm
2020-04-01Rainer J. BoehmDirectorBuy13,750.001.2016,500.00417,338.00https://www.sec.gov/Archives/edgar/data/1293310/000121465920003154/0001214659-20-003154-index.htm
2020-09-30Cheryl BuxtonDirectorBuy1,284.0010.6413,661.764,364.00https://www.sec.gov/Archives/edgar/data/1293310/000121465920008368/0001214659-20-008368-index.htm
2020-05-20RONALD BARLIANTDirectorBuy26,847.000.8623,088.42449,351.00https://www.sec.gov/Archives/edgar/data/1293310/000121465920004950/0001214659-20-004950-index.htm
2020-01-22Cheryl BuxtonDirectorBuy4,576.000.381,738.884,576.00https://www.sec.gov/Archives/edgar/data/1293310/000121465920000574/0001214659-20-000574-index.htm
2020-09-30Rainer J. BoehmDirectorBuy1,519.0010.6416,162.1684,986.00https://www.sec.gov/Archives/edgar/data/1293310/000121465920008352/0001214659-20-008352-index.htm